Infliximab treatment of severe ankylosing spondylitis: One-year followup
Open Access
- 10 December 2001
- journal article
- letter
- Published by Wiley in Arthritis & Rheumatism
- Vol. 44 (12) , 2936-2937
- https://doi.org/10.1002/1529-0131(200112)44:12<2936::aid-art483>3.0.co;2-m
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Successful treatment of active ankylosing spondylitis with the anti–tumor necrosis factor α monoclonal antibody infliximabArthritis & Rheumatism, 2000
- Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot studyAnnals of the Rheumatic Diseases, 2000
- Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritisArthritis & Rheumatism, 1998
- Evaluation of Diagnostic Criteria for Ankylosing SpondylitisArthritis & Rheumatism, 1984